Introduction {#Sec1}
============

Anemia is common in patients with chronic kidney disease (CKD); severe anemia can reduce quality of life, and increase the risk of cardiovascular (CV) events and mortality \[[@CR1], [@CR2]\]. Anemia management is central in care for patients with CKD, and treatment with iron and erythropoiesis-stimulating agents (ESAs) is the standard of care for patients on dialysis. Therapeutic goals include correcting anemia and maintaining stable hemoglobin (Hb) levels. Reduced ESA dose and frequency of administration should also be sought \[[@CR3], [@CR4]\]. A recent systematic review and meta-analysis of randomized trials in patients with CKD analyzed data from more than 12,000 patients in 40 trials with the aim of comparing the efficacy and safety of ESAs \[[@CR5]\]. The conclusion was that epoetins (epoetin alfa, epoetin beta; darbepoetin alfa, methoxy polyethylene glycol-epoetin beta) were similarly effective for preventing blood transfusion and better than placebo and that currently all ESAs are safe and efficacious with minimal differences between the different formulations in the CKD setting.

Despite well-defined therapeutic goals, maintaining Hb within the desired range is challenging in patients with CKD: many factors, including iron status and comorbidities, influence the response to treatment. Continuous erythropoiesis receptor activator \[C.E.R.A. (methoxy polyethylene glycol-epoetin beta)\] \[[@CR6]\] has a long half-life (134 h), a relatively low binding affinity for the erythropoietin receptor and low systemic clearance, allowing once-monthly (QM) dosing, which may be more convenient for patients compared with shorter-acting ESAs \[[@CR6], [@CR7]\].

A variety of Phase II and III trials of C.E.R.A. have been conducted in CKD. Data from 13 Phase III trials set up with similar design were pooled for this analysis, each multicenter study set up using similar inclusion and exclusion criteria and trial design to allow analyses to be performed both at the single-study level and using pooled data from multiple studies. Data from individual studies in dialysis-dependent patients with CKD have demonstrated that C.E.R.A. QM maintains stable on-target Hb concentrations with fewer dose adjustments than shorter-acting ESAs \[[@CR7]--[@CR16]\]. Pooling data from similar individual studies allows investigating the efficacy and safety of C.E.R.A. in clinically relevant subgroups of patients with CKD, where underlying risk factors can potentially affect patients' response to treatment.

The present pool comprises 13 similarly designed studies investigating the efficacy and safety of C.E.R.A. QM in 2060 dialysis patients. Studies were conducted in real-life settings across numerous countries between 2007 and 2011. The aim of this analysis was to determine whether the efficacy and safety of C.E.R.A. is affected by CV risk factors, age, gender, or protocol-defined Hb target ranges.

Methods {#Sec2}
=======

For this analysis, data from 13 interventional, open-label, multicenter trials included in the Umbrella C.E.R.A. program (ClinicalTrials.gov identifiers: NCT00413894/NCT00545571/NCT00517413/NCT00560404/NCT00882713/NCT00550680/NCT00576303/NCT00660023/NCT00717821/NCT00642850/NCT00605293/NCT00661505/NCT00699348) conducted in 404 centers across Brazil, Czech Republic, France, Germany, Greece, Hungary, Italy, Latin America, Morocco, Russia, Spain, Switzerland and Turkey were pooled (Supplementary Table 1). Ten single-arm and three 2-arm randomized trials were run under an Umbrella protocol to ensure similar populations and similar treatment regimens. All patients from the 10 single-arm trials and patients from the C.E.R.A. arm of the three randomized trials have been combined for this Umbrella analysis.

Ethics Statement {#Sec3}
----------------

Studies were conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2013, and the protocols were approved by the Institutional Review Boards/local Independent Ethics Committees at each center. Written informed consent was obtained from all participants. Data analyzed in this manuscript are from previously published studies.

Subjects, Inclusion and Exclusion Criteria {#Sec4}
------------------------------------------

Inclusion and exclusion criteria were similar across studies. Patients (≥18 years) with chronic renal anemia on hemodialysis meeting the following criteria were eligible: Hb concentration within the study's target range, adequate iron status \[serum ferritin \>100 ng/mL [and]{.ul} transferrin saturation (TSAT) \>20% [or]{.ul} hypochromic red cells \<10%\], continuous ESA maintenance therapy with unchanged dosing interval and weekly dose during the previous month, regular long-term dialysis with identical mode of dialysis for at least 3 previous months.

Exclusion criteria were relevant acute or chronic bleeding, or erythrocyte transfusion within the preceding 8 weeks, hemoglobinopathy or known hemolysis, active malignant disease, vitamin B12 or folic acid deficiency, pure red cell aplasia, platelet count \>500 × 10^9^/L or \<100 × 10^9^/L, poorly controlled hypertension, myocardial infarction, stroke, severe/unstable coronary artery disease, severe liver disease during the previous 3 months or severe congestive heart failure (New York Heart Association class IV).

Study Design {#Sec5}
------------

Patients with chronic renal anemia on dialysis (Table [1](#Tab1){ref-type="table"}) receiving ESA treatment entered a 4- to 8-week screening period, during which mean Hb concentrations were maintained within the study's target range (10--12 or 10.5--13 g/dL). Patients then entered a 16-week C.E.R.A. dose-titration period followed by an 8-week evaluation period (Fig. [1](#Fig1){ref-type="fig"}), with Hb concentrations assessed during screening, titration and evaluation. Subgroups were defined based on: Hb target range (lower, 10.0--12.0 g/dL/upper, 10.5--13.0 g/dL); gender (F/M); age (\<65/≥65); baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\<5000/≥5000, a 5000 ng/mL cut-off was predictive for various endpoints \[[@CR17]\]); CV risk factors (diabetes/cardiac/vascular/none). Patients were further subdivided per quintiles of C.E.R.A. dose (µg: q1 ≤ 70; q2 = 70--110; q3 = 110--125; q4 = 125--185; q5 ≥ 185), Hb (g/dL: q1 ≤ 10.65; q2 = 10.65--11.2; q3 = 11.2--11.7; q4 = 11.7--12.25; q5 ≥ 12.25), and C-reactive protein (CRP) (mg/L: q1 ≤ 2.26; q2 = 2.26--4.14; q3 = 4.14--7.21; q4 = 7.21--14; q5 ≥ 14).Table 1Studies, countries and hemoglobin target ranges included in the pooled analysisStudyNCT numberCountryNumber (%) of patientsHemoglobin target range (g/dL)Hemoglobin target range groupML21040NCT00642850Czech Republic155 (7.5)10.0--12.0LowerML21145NCT00717821France225 (10.9)10.0--12.0LowerML20752NCT00660023Hungary107 (5.2)10.0--12.0LowerML21438NCT00699348Italy298 (14.5)10.0--12.0LowerML21060NCT00605293Spain48 (2.3)10.0--12.0LowerML21096NCT00661505Turkey102 (5.0)10.0--12.0LowerML21208NCT00560404Brazil76 (3.7)10.5--12.5UpperML20952NCT00550680Greece152 (7.4)10.5--12.5UpperML20881NCT00517413Latin America129 (6.3)10.5--12.5UpperML21797NCT00882713Morocco182 (8.8)10.5--12.5UpperML20977NCT00576303Russia178 (8.6)10.5--12.5UpperML20572NCT00413894Germany344 (16.7)11.0--12.5UpperML20826NCT00545571Switzerland64 (3.1)11.0--13.0UpperIndividual study results are summarized as supporting information (Supplementary Table 1) and accessible on <http://www.roche-trials.com>Fig. 1Common study design. In all 13 studies, enrolled patients entered a 4- to 8-week screening period followed by a 16-week C.E.R.A. dose-titration period, and an 8-week evaluation period. *C.E.R.A.* continuous erythropoietin receptor activator, *ESA* erythropoiesis-stimulating agents

Study Treatment {#Sec6}
---------------

Patients continued to receive epoetin or darbepoetin during screening, with no dose interval changes. C.E.R.A. (Micera^®^, F. Hoffmann-La Roche Ltd., Basel, Switzerland) was administered during dose titration and evaluation. The starting C.E.R.A. dose was based on the last dose of previous ESA, according to the Summary of Product Characteristics: \<8000 international units (IU) epoetin or \<40 µg darbepoetin alfa = 120 µg (or 125 µg in study ML20572) C.E.R.A.; 8000--16,000 IU epoetin or 40--80 µg darbepoetin alfa = 200 µg C.E.R.A.; \>16,000 IU epoetin or \>80 µg darbepoetin alfa = 360 µg C.E.R.A. \[[@CR18]\].

C.E.R.A. doses were adjusted during titration and evaluation at the investigator's discretion to maintain Hb within the pre-defined target range of each individual study.

Efficacy and Safety Comparisons in Defined Subgroups {#Sec7}
----------------------------------------------------

Efficacy endpoints were Hb concentration, Hb fluctuation, proportion of patients maintaining Hb stability (Hb concentration change ≤1.0 g/dL from screening to evaluation period or maintained within the target range), required dose of C.E.R.A. and dose adjustments.

Safety endpoints for comparative subgroup analyses were the number of adverse events (AEs) and serious AEs (SAEs), cardiac events and serious CV events, thromboembolic events (including vascular access thrombosis), hypertensive events (including reports of hypertension, hypertensive crisis and blood pressure fluctuation) and vascular disorders (without hypertensive events) e.g., stenosis, phlebitis, arteriosclerosis.

At each study visit, routine laboratory measurements were conducted. Relevant tests known to correlate with ESA response were: transferrin saturation, ferritin, and CRP. Additionally, an ESA resistance index was computed: the rank of the cumulative ESA dosing in the screening period (before switching to C.E.R.A.) over the rank of the average Hb during the screening period \[[@CR19], [@CR20]\]. In most studies NT-proBNP was measured at baseline.

Statistical Methods {#Sec8}
-------------------

This analysis included patients who reached the efficacy evaluation period (intention-to-treat completers).

Average Hb concentrations for a particular period were based on all Hb assessments during that period. If *H*~0~,...,*H*~*n*~ are taken at timepoints *t*~0~,...,*t*~*n*~, the time-adjusted average Hb value per patient (Hb concentration) was calculated by:$$\documentclass[12pt]{minimal}
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Hb fluctuation was estimated by a successive variation measure according to the following formula:$$\documentclass[12pt]{minimal}
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This fluctuation measure is less prone to overall trends in Hb development compared with usual standard deviation (SD) measures.

Overall Hb stability was the proportion of patients maintaining Hb concentration within ±1.0 g/dL from the screening to the evaluation period or staying within target range of the pertaining study.

Differences between subgroups were tested by *t* tests or Wilcoxon rank sum tests for metric variables or Chi-square tests for categorical variables.

A word of statistical caution: this study's database is large; therefore even small differences between groups can become statistically significant. Differences should be judged by their relative size and potential clinical relevance, not by formal statistical significance. In order to avoid spurious significance, *p* values \<0.01 were considered statistically significant.

Results {#Sec9}
=======

Study Population {#Sec10}
----------------

In total, 2060 patients \[mean (SD) age 60.6 (15.6) years, 57.6% male\] from 13 studies were included in the analysis. Demographic and baseline characteristics are summarized in Table [2](#Tab2){ref-type="table"}. The largest renal disease etiology subgroups were hypertension \[*n* = 487 (28%)\], diabetes \[*n* = 351 (21%)\] and glomerulonephritis \[*n* = 318 (19%)\] (percentages based on patients with defined etiology). In total, 1508 patients (73%) had ≥1 prior disease/risk factor, the most common being vascular disorders (68%) and metabolism/nutrition disorders (38%). Most patients (81%) received epoetin during screening; 43% received epoetin alfa, 38% epoetin beta, and 28% darbepoetin. Some patients had a change in ESA medication during the screening period, thus numbers add to over 100%.Table 2Demographic characteristics of patients (*n* = 2060)Male, *n* (%)1186 (57.6)Mean age, years ± SD61 ± 15.6Mean weight, kg ± SD71 ± 15.2Mean height, cm ± SD166 ± 9.7Ethnicity, *n* (%) White1533 (74) Hispanic or Latino53 (3) Black29 (1) Other38 (2) Unknown445 (22)Etiology of renal disease, *n* (%) Hypertension/large vessel disease487 (28) Glomerulonephritis318 (19) Diabetes351 (21) Interstitial nephritis/pyelonephritis217 (13) Polycystic kidney disease109 (6) Sec. glomerulonephritis/vasculitis56 (3) Other hereditary/congenital diseases35 (2) Neoplasms/tumors34 (2) Other160 (9) Undefined etiology315 (18)Prior diseases/risk factors Vascular disorders1397 (68) Metabolism and nutrition disorders778 (38) Cardiac disorders390 (19) Surgical and medical procedures317 (15) Nervous system disorders151 (7) Gastrointestinal disorders110 (5) Infections and infestations29 (1) Respiratory, thoracic and mediastinal disorders19 (1)ESA administration during screening, % Epoetin alfa43 Epoetin beta38 Darbepoetin alfa28 Other2*ESA* erythropoiesis-stimulating agent, *SD* Standard deviation

Patients were divided into subgroups as follows: lower/upper Hb target range (*n* = 935/*n* = 1125); male/female (*n* = 1186/*n* = 874); \<65/≥65 years (*n* = 1090/*n* = 932); low/high baseline NT-proBNP (*n* = 975/*n* = 624); patients with diabetes (*n* = 535), with cardiac risk factors (*n* = 565), with vascular risk factors (*n* = 1675), with no CV risk factors (*n* = 283).

Efficacy {#Sec11}
--------

As seen previously \[[@CR6], [@CR7]\], the overall population achieved stable Hb concentrations throughout screening, titration and evaluation periods, and exhibited Hb fluctuations \~0.5 g/dL during evaluation. The mean Hb level was 11.4 g/dL during both screening and evaluation and was 11.7 g/dL during titration. A high proportion of patients exhibited Hb stability (Hb concentration within ±1 g/dL from screening or within the target range) (Fig. [2](#Fig2){ref-type="fig"}). Overall, patients required an average C.E.R.A. dose of 133.4 µg during titration and 131.3 µg during evaluation. During titration, patients received 8220 C.E.R.A. administrations in total; dose changes were required in 3078 cases (37.4%). During the evaluation period, patients received a total of 4103 doses; dose changes were required in 737 cases (18.0%). Efficacy within different subgroups during the evaluation period is considered in detail below.Fig. 2Proportion of patients exhibiting hemoglobin stability. Across all studied subgroups, a large majority of patients (76--80%) exhibited hemoglobin stability (hemoglobin concentration within ±1 g/dL from screening or within the target range, evaluation period). *CV* cardiovascular, *L* lower, *NT*-*proBNP* N-terminal pro-B-type natriuretic peptide, *U* upper

### Hemoglobin Target Range {#Sec12}

Mean achieved Hb in the lower and upper Hb target groups differed by 0.4 g/dL (11.2 vs 11.6; *p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). Hb fluctuations were also higher in the upper Hb group (0.46 vs 0.50; *p* = 0.001) (Table [3](#Tab3){ref-type="table"}), whereas Hb stability or dose changes did not differ significantly between target range groups. Patients with lower target Hb range required significantly lower C.E.R.A. doses than the upper Hb target subgroup (124.7 vs 136.9 µg; *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}). Iron status and CRP values were not significantly different in the two Hb target groups; they were slightly more favorable in the upper group (data not shown). ESA resistance index and baseline NT-proBNP were also closer to normal values in the upper target group than in the lower: median TSAT 28.8% vs 27.5% (*p* = 0.05); median ferritin 456.5 vs 465.0 µg/L (*p* = 0.43); median CRP 4.4 vs 4.7 mg/L (*p* = 0.22); median ESA resistance index 0.8 vs 1.4 (*p* \< 0.001); median NT-proBNP (pg/mL) 2982 vs 4047 (*p* \< 0.001).Table 3Efficacy comparisons between subgroups during evaluationNumber of patientsHemoglobin (g/dL)Hemoglobin fluctuation (g/dL)Overall stability (%)Average monthly dose (µg)% dose changesDose changes per patientAll206011.40.4878131.318.00.4Target group L93511.2*0.46*80*124.7*19.10.4Target group U112511.6*0.50* ^b^77*136.9* ^b^17.10.3Female87411.40.4880131.017.20.3Male118611.50.4877131.618.50.4Age \<65109011.5*0.5*77131.518.40.4Age ≥6593211.4*0.45* ^a^80129.317.50.4NT-proBNP \<5000975^e^11.40.4778*124.3*18.10.4NT-proBNP ≥5000624^e^11.40.4980*138.0* ^c^18.20.4No CV risk28311.5*0.51*78127.817.70.4Cardiac risk56511.4*0.46* ^d^78136.218.00.4Vascular risk167511.40.4879132.218.10.4Diabetes at baseline53511.30.4776132.517.40.3Italicized values indicate significant differences (*p* \< 0.01) between subgroups: ^a^ *p* \< 0.001; ^b^ *p* = 0.001; ^c^ *p* = 0.002; ^d^ *p* = 0.01^e^NT-proBNP was not measured for all patients*CV* cardiovascular, *L* lower, *NT*-*proBNP* N-terminal pro-B-type natriuretic peptide, *U* upperFig. 3Mean Hb levels over time, by target Hb group. The *error bars* show 95% confidence intervals. In the *upper* (*square symbols*) and the *lower* (*triangle symbols*) Hb target groups, the achieved Hb levels were stable over time. *Hb* hemoglobin

### Gender {#Sec13}

All efficacy outcomes were similar across male and female subgroups (Table [3](#Tab3){ref-type="table"}).

### Age {#Sec14}

Achieved Hb concentrations, Hb stability, dose changes required, or C.E.R.A. dose required were not significantly different in patients aged ≥65 years and those \<65 years (Table [3](#Tab3){ref-type="table"}). However, Hb fluctuation values were significantly higher in patients aged \<65 years (0.51 vs 0.45 g/dL; *p* \< 0.001) (Table [3](#Tab3){ref-type="table"}).

### Baseline NT-proBNP Levels {#Sec15}

Patients in the high and low NT-proBNP subgroups did not have significantly different Hb concentrations, Hb fluctuation, Hb stability or required dose changes (Table [3](#Tab3){ref-type="table"}). However, those in the low NT-proBNP group required significantly lower C.E.R.A. doses than those in the high group (124.3 vs 138.0 µg; *p* = 0.002) (Table [3](#Tab3){ref-type="table"}). The iron status was slightly higher in the low NT-proBNP subgroup than in the high subgroup, while CRP values and ESA resistance index were significantly lower (more favorable) in the low NT-proBNP group than in the high group (Table [4](#Tab4){ref-type="table"}).Table 4Median TSAT, ferritin, CRP and ESA resistance index in subgroups according to NT-proNBP levels high (\>5000 ng/mL) or low (≤5000 ng/mL)VariableBaseline NT-proNBP level*p* valueLow\
*n* = 975High\
*n* = 624TSAT, %29.828.20.05Ferritin, µg/L430.0470.00.11CRP, mg/L*4.05.00.003*ESA resistance index*1.11.3*\<*0.001*Italicized values indicate significant differences (*p* \< 0.01) between subgroups*CV* cardiovascular, *CRP* C-reactive protein, *ESA* erythropoiesis-stimulating agent, *NT*-*proBNP* N-terminal pro-B-type natriuretic peptide, *TSAT* transferrin saturation

### Cardiovascular Risk Factors {#Sec16}

Achieved Hb concentrations, Hb stability, required C.E.R.A. dose and dose changes were not significantly different in patients with pre-existing CV risk factors and patients with no CV risk factors (Table [3](#Tab3){ref-type="table"}). Hb fluctuation values were significantly different between those with pre-existing cardiac risk factors and those without CV risk factors (0.46 vs 0.51 g/dL; *p* = 0.01) (Table [3](#Tab3){ref-type="table"}). Furthermore, a trend towards lower dose requirements in the group with no CV risk factors was observed. TSAT values were slightly favorable for the no CV risk group compared with patients with diabetes, cardiac or vascular complications, whereas the opposite was seen for ferritin (Table [5](#Tab5){ref-type="table"}). Likewise, CRP values were lower for the no CV risk group compared with those with diabetes, cardiac or vascular complications, while a higher resistance index was seen in the no CV risk group (Table [5](#Tab5){ref-type="table"}). Baseline NT-proBNP levels were significantly lower in the no CV risk group compared with the other subgroups (Table [5](#Tab5){ref-type="table"}).Table 5Median TSAT, ferritin, CRP, ESA resistance index and NT-proNBP levels according to CV risk groupNo CV risk\
*n* = 283Diabetes\
*n* = 535*p* valueCardiac risk factors\
*n* = 565*p* valueVascular risk factors\
*n* = 1675*p* valueTSAT, %*29.627.10.00826.5*\<*0.001*28.10.02Ferritin, μg/L428.5494.00.05487.90.0054650.07CRP, mg/L4.05.00.15.10.034.60.51ESA resistance index1.21.00.02*0.9*\<*0.001*1.00.04NT-proNBP, pg/mL*25443463*\<*0.0015477*\<*0.0013753*\<*0.001*Italicized values indicate significant differences (*p* ≤ 0.01) between subgroups (risk group versus no CV risk)*CV* cardiovascular, *CRP* C-reactive protein, *ESA* erythropoiesis-stimulating agent, *NT*-*proBNP* N-terminal pro-B-type natriuretic peptide, *TSAT* transferrin saturation

Safety {#Sec17}
------

Overall safety results from individual studies have been reported in the respective publications and study reports. This section focusses on differences in safety outcomes between analyzed patient subgroups.

Compared with patients aged \<65 years, those aged ≥65 years experienced higher incidences of AEs (59.4% vs 72.0%, *p* \< 0.001), SAEs (20.0% vs 30.8%, *p* \< 0.001), cardiac AEs (4.7% vs 8.7%, *p* \< 0.001) and thromboembolic AEs (1.3% vs 3.4%, *p* = 0.003) (Table [6](#Tab6){ref-type="table"}). Patients with a baseline NT-proBNP level ≥5000 experienced higher AE incidences compared with those in the low NT-proBNP group, including all AEs (59.1% vs 65.9%, *p* = 0.007), SAEs (19.4% vs 27.4%, *p* \< 0.001), cardiac AEs (3.3% vs 9.0%, *p* \< 0.001) and serious CV AEs (2.5% vs 5.3%, *p* \< 0.005) (Table [6](#Tab6){ref-type="table"}). Overall, patients with pre-existing risk factors also experienced higher AE incidences compared with patients with no CV risk factors (Table [6](#Tab6){ref-type="table"}).Table 6Safety outcomesNumber of patientsAny AE (%)Any SAE (%)Cardiac AE (%)Serious CV-AE (%)Thromboembolic AE (%)Hypertensive AE (%)Vascular AE (%)All20606524.96.53.92.97.71.6Target Group L93566.524.95.94.22.98.12.3Target Group U112563.722.46.93.72.97.31.1Female87466.125.75.83.72.77.91.8Male118664.224.26.94.13.07.51.4Age \<651090*59.420.04.7*3.5*1.3*7.71.6Age ≥65932*72.0* ^a^*30.8* ^a^*8.7* ^a^4.4*3.4* ^b^7.61.6NT-proBNP \<5000975^f^*59.119.43.32.5*2.56.91.1NT-proBNP ≥5000624^f^*65.9* ^d^*27.4* ^a^*9.0* ^a^*5.3* ^c^3.09.62.2No CV risk283*45.917.02.11.42.52.80.0* Cardiac risk565*71.7* ^e^*34.4* ^e^*11.0* ^e^*6.2* ^e^*4.4* ^e^*8.9* ^e^*2.5* ^e^ Vascular risk1675*64.3* ^e^*26.4* ^e^*7.1* ^e^*4.5* ^e^*2.9* ^e^*8.7* ^e^2.0 Diabetes at baseline535*71.2* ^e^*33.6* ^e^*7.3* ^e^*5.4* ^e^*5.4* ^e^*6.4* ^e^2.1Italicized values represent differences (*p* \< 0.01) between subgroups: ^a^ *p* \< 0.001; ^b^ *p* \< 0.003; ^c^ *p* \< 0.005; ^d^ *p* = 0.007; ^e^ *p* \< 0.01. For cardiac risk, vascular risk and diabetes at baseline the comparison is with no CV risk^f^NT-proBNP was not measured for all patients*AE* adverse event, *CV* cardiovascular, *L* lower, *NT*-*proBNP* N-terminal pro-B-type natriuretic peptide, *SAE* serious AE, *U* upper

In the two highest C.E.R.A. dose quintiles, and in the two lowest Hb quintiles, a slight increase in the rate of cardiac AEs was observed (Fig. [4](#Fig4){ref-type="fig"}). In the highest dose group, the percentage of patients experiencing serious CV AEs (6.3%), thromboembolic AEs (5.1%), and vascular AEs (2.4%) was higher than in all other dose quintiles. Contrastingly, similar frequencies of serious CV, thromboembolic and vascular AEs were recorded across the first four Hb quintiles, and lowest values were observed in the fifth quintile; thus, there was no relationship between Hb level and rate of CV AEs. Finally, high CRP levels appear to be associated with increased serious, thromboembolic and vascular AEs: thromboembolic AEs occurred in 5.0% of patients in the two highest quintiles compared with 3.2% in the other quintiles, with a similar pattern seen for serious AEs (3.9% vs 2.2%) and vascular AEs (2.3% vs 1.1%).Fig. 4Percentage of patients with CV AEs per dose, Hb and CRP quintile. The proportion of patients experiencing cardiac, serious CV, thromboembolic, and vascular AEs is shown by quintiles of Hb, C.E.R.A. dose and CRP. *AE* adverse event, *C.E.R.A.* continuous erythropoietin receptor activator, *CRP* C-reactive protein, *CV* cardiovascular, *Hb* hemoglobin

Discussion {#Sec18}
==========

This retrospective analysis of 13 trials included in the Phase III C.E.R.A. clinical program evaluated the efficacy and safety of C.E.R.A. in clinically relevant patient subgroups of patients with CKD on hemodialysis, confirming and extending the findings of an earlier poster presentation of some of these subgroups \[[@CR22]\] and an earlier pooled analysis of safety in both dialysis and non-dialysis patients, which concluded that C.E.R.A. showed an overall safety profile comparable with other ESAs \[[@CR21]\]. In the current analysis, C.E.R.A. QM maintained stable Hb concentrations uniformly across all subgroups considered, including those with elevated risk profiles.

The Phase III program included numerous trials of similar design, allowing pooled analysis of results, but the limitations of such an approach should be recognized. All of the analyses were of single arms without a comparator group. While the trials were designed within the same framework as part of an umbrella program, they were performed in different countries and were by no means identical. The post hoc nature of the analysis is also an important limitation, as comparisons were neither pre-planned nor suitably powered to determine significant efficacy and safety differences between subgroups.

Most significant differences between subgroups were numerically small and may not be clinically relevant. The proportion of patients demonstrating Hb stability was similar across all subgroups, with the lowest value (76%) in patients with diabetes. Mean Hb fluctuations were around 0.5 g/dL across all subgroups, independent of Hb target, gender and pre-existing CV risk factors.

The favorable efficacy, safety and tolerability profile of C.E.R.A. in the general CKD population had been reported previously \[[@CR7]--[@CR12], [@CR15], [@CR16]\]. The impact of low Hb on mortality and CV morbidity was demonstrated in retrospective analyses of nine Phase III, randomized, controlled trials involving 3405 patients with anemic CKD treated with C.E.R.A. \[[@CR23]\]. In these analyses, average Hb level \<10 g/dL, decrease from stable baseline Hb \>1 g/dL, last Hb level \<10 g/dL, Hb decline \>1.5 g/dL/4 weeks and increased Hb variability were associated with a higher risk of the composite endpoint and all-cause mortality.

In our analysis, despite stable Hb maintenance across patient subgroups, there were notable differences in the C.E.R.A. dose required. As expected, patients in the upper Hb target group required higher doses than those in the lower target group; however, the mean value required for the upper Hb target group (136.9 µg) was relatively low despite the difference being statistically significant. Iron status, CRP, NT-proBNP and ESA resistance index were comparable between subgroups or closer to adequate in the upper target group than the lower, suggesting that dose requirement differences were due to varying target ranges rather than deficiency in ESA-response background variables. The higher doses needed in the high NT-proBNP group compared with the low subgroup may be due to volume overload, hemodilution or underlying diseases such as chronic cardiac congestive failure \[[@CR24], [@CR25]\]. Indeed, high NT-proBNP levels are thought to result from the inflammatory process consequent to cardiac diseases and impaired renal function \[[@CR25]\]. Iron status was comparable between the two NT-proBNP groups; however, CRP and ESA resistance index were slightly lower in the low group. Whether these differences can explain the variation in required dose in the two subgroups is uncertain: chronic cardiac congestive failure would not correlate strongly with CRP or iron status. Notably, the proportion of C.E.R.A. dose modifications required was low to moderate across all subgroups.

We acknowledge that caution should be taken when interpreting statistically significant figures that lack clinical plausibility. Likewise, non-significant differences do not provide categorical proof that no difference exists between subgroups. For example, the non-significant trend towards lower dose requirements in no-CV risk patients is supported by elevated NT-proBNP levels in patients with pre-existing CV risk factors, reinforcing the observation that NT-proBNP levels may be predictive for higher C.E.R.A. dose requirements.

Safety outcomes were as expected across subgroups. Neither Hb target range nor gender influenced the incidence of AEs; however, all AEs, SAEs, cardiac AEs and serious CV AEs were significantly higher in patients with underlying risk factors (older age, high NT-proBNP or pre-existing CV risk factors) compared with their lower risk counterparts. Non-significant differences in the incidences of thromboembolic and vascular AEs were also observed between subgroups. Observations in the NT-proBNP subgroups are supported by a recent analysis in end-stage renal disease patients on dialysis, where high baseline NT-proBNP levels predicted higher incidences of cardiac and CV endpoints (5000 ng/mL) \[[@CR17]\]. Moreover, elevated NT-proBNP levels have been revealed as an independent mortality predictor in incident hemodialysis patients \[[@CR25]\]. While baseline NT-proBNP level was not predictive for hypertensive AEs, pre-existing CV risk factors were. Overall, the increase in CV AEs experienced with pre-existing CV risk factors suggests AEs were not related to C.E.R.A. administration.

CV AEs of interest were analyzed by quintiles of Hb, C.E.R.A. dose and CRP. A slight increase in AE rates was observed in the quintiles with lowest Hb levels and highest doses. These findings agree with previous observations and clinical guidelines that recommend conservative Hb targets (10--12 g/dL), individualized for each patient's comorbidities. If ESA therapy is used in patients hyporesponsive to ESA treatment, aiming towards the lower Hb levels of the target range is recommended \[[@CR3], [@CR26]\].

Furthermore, our data showed that chronic elevation of CRP levels was associated with increased thromboembolic and vascular AEs. This agrees with previous observations that suggest CRP---a marker of inflammation---constitutes an independent risk factor for CV disease \[[@CR27]\]. Caution should be used in patients hyporesponsive to ESA treatment having high CRP levels or in those with specific risk factors (especially diabetics) or conditions such as symptomatic limb arteriopathy, stroke or non-symptomatic ischemic heart disease, or cancer \[[@CR27]\].

Conclusion {#Sec19}
==========

C.E.R.A. QM maintained stable Hb concentrations with moderate fluctuations across subgroups of patients with chronic renal anemia on dialysis switching from maintenance therapy with shorter-acting ESAs, including those with underlying risk factors. Differences in required C.E.R.A. doses were observed between patients with upper and lower Hb target levels, and with high and low baseline NT-proBNP levels. The safety profile across subgroups was as expected based on pre-existing risk factors; any increases in AEs were related to underlying risk factors rather than to the study drug.
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